Core Insights - The CSI Medical Index (399989) closed at 7552.84 points, up 1.42%, with a trading volume of 20.99 billion yuan and a turnover rate of 1.72% [1] - Among the index constituents, 40 stocks rose, with Jiuzhou Pharmaceutical leading at a 6.04% increase, while 10 stocks fell, with BGI Genomics leading the decline at 2.93% [1] Index Constituents Summary - The top ten constituents of the CSI Medical Index include: - WuXi AppTec (603259) with a weight of 14.78%, latest price at 99.46, and a 3.69% increase [1] - Mindray Medical (300760) with a weight of 8.91%, latest price at 230.50, and a slight decrease of 0.08% [1] - United Imaging Healthcare (688271) with a weight of 8.15%, latest price at 148.36, and a 0.38% increase [1] - Aier Eye Hospital (300015) with a weight of 6.25%, latest price at 12.68, and a 0.16% increase [1] - Kanglong Chemical (300759) with a weight of 3.44%, latest price at 31.35, and a 4.33% increase [1] - Tigermed (300347) with a weight of 3.26%, latest price at 55.07, and a 2.51% increase [1] - Aimeike (300896) with a weight of 2.98%, latest price at 175.15, and a slight decrease of 0.19% [1] - New Industry (300832) with a weight of 2.92%, latest price at 62.62, and a decrease of 0.98% [1] - Huatai Medical (688617) with a weight of 2.91%, latest price at 311.26, and a slight decrease of 0.08% [1] - Yuyue Medical (002223) with a weight of 2.55%, latest price at 38.00, and a 0.66% increase [1] Capital Flow Analysis - The CSI Medical Index constituents experienced a net inflow of 397 million yuan from institutional investors, while retail investors saw a net outflow of 204 million yuan [3] - Key stocks with significant capital flow include: - Meinian Health (002044) with a net inflow of 88.56 million yuan from institutional investors [3] - Aier Eye Hospital (300015) with a net inflow of 81.55 million yuan from institutional investors [3] - Mindray Medical (300760) with a net inflow of 79.59 million yuan from institutional investors [3] - Jiuzhou Pharmaceutical (603456) with a net inflow of 62.91 million yuan from institutional investors [3] - Huatai Medical (688617) with a net inflow of 28.38 million yuan from institutional investors [3]

证券代码：603456 证券简称：九洲药业 公告编号：2025-061 浙江九洲药业股份有限公司 关于 2025 年前三季度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次计提资产减值准备的概况 根据《企业会计准则》以及公司会计政策的相关规定，为更加真实、准确地 反映公司截至 2025 年 9 月 30 日的资产状况和财务状况，公司及子公司对存在减 值迹象的资产采取必要的减值测试和评估，基于谨慎性原则，对可能发生资产减 值损失的资产计提减值准备，具体情况如下： | | 项目 | 2025 年前三季度计提减值损失金额（万元） | | | --- | --- | --- | --- | | 信用减值损失 | 应收账款坏账损失 | | -2,054.18 | | | 其他应收款坏账损失 | | -29.58 | | | 小计 | | -2,083.76 | | 资产减值损失 | 商誉减值损失 | | 71.66 | | | 存货跌价损失 | | 8,965.71 | | | 工程物资减值损失 | | ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-060 浙江九洲药业股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 10 月 31 日 14 点 00 分 召开地点：浙江九洲药业股份有限公司会议室（浙江省台州市椒江区外沙路 99 号） (五)网络投票的系统、起止日期和投票时间。 股东大会召开日期：2025年10月31日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 10 月 31 日 至2025 年 10 月 31 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 证券代码：603456 证券简称：九洲药业 公告编号：2025-058 浙江九洲药业股份有限公司 第八届监事会第十一次会议决议公告 浙江九洲药业股份有限公司（以下简称"公司"）第八届监事会第十一次会 议于 2025 年 10 月 15 日以现场表决结合通讯表决的方式召开。本次监事会已于 2025 年 10 月 10 日以电子邮件、电话、传真等方式通知全体董事、监事、高级 管理人员。会议由孙蒙生先生主持，会议应出席监事 3 名，实际出席监事 3 名。 本次会议参与表决人数及召集、召开程序符合《公司法》和《公司章程》的有关 规定，合法有效。 二、监事会会议审议情况 1、审议通过了《关于公司 2025 年第三季度报告的议案》； 监事会对董事会编制的公司 2025 年第三季度报告进行了认真审核，认为： 公司 2025 年第三季度报告详见《上海证券报》和上海证券交易所网站 （www.sse.com.cn）披露的公告。 表决结果：同意：3 票；反对：0 票；弃权：0 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江九洲药业股份有限公司（以下简称"公司"）第八届董事会第十七次会议 于2025年10月15日以现场表决结合通讯表决的方式召开。本次董事会已于2025 年 10 月 10 日以电子邮件、电话等方式通知全体董事、监事、高级管理人员。会 议应出席董事 9 人，实际出席董事 9 人。全体董事推举董事长花莉蓉女士主持本 次会议，本次会议参与表决人数及召集、召开程序符合《公司法》和《公司章程》 的有关规定，合法有效。 二、董事会会议审议情况 1、审议通过了《关于公司 2025 年第三季度报告的议案》； 公司《2025 年第三季度报告》详见《上海证券报》和上海证券交易所网站 （www.sse.com.cn）。 证券代码：603456 证券简称：九洲药业 公告编号：2025-057 浙江九洲药业股份有限公司 第八届董事会第十七次会议决议公告 表决结果：同意：9 票；反对：0 票；弃权：0 票。 本议案已经第八届董事会审计委员会第十一次会议审议通过。 2、审议通过了《关于 ...

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) reported a revenue of 4.16 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 4.92% [1] - The net profit attributable to shareholders reached 748 million yuan, marking an 18.51% increase year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 746 million yuan, showing a year-on-year growth of 20.67% [1] Financial Performance - Revenue for the first three quarters: 4.16 billion yuan, up 4.92% year-on-year [1] - Net profit attributable to shareholders: 748 million yuan, up 18.51% year-on-year [1] - Net profit after deducting non-recurring gains and losses: 746 million yuan, up 20.67% year-on-year [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) reported a revenue of 4.16 billion yuan for the first three quarters, reflecting a year-on-year growth of 4.92% [1] - The net profit attributable to shareholders reached 748 million yuan, marking an 18.51% increase year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 746 million yuan, showing a year-on-year growth of 20.67% [1] - Basic earnings per share stood at 0.84 yuan [1] Financial Performance - Revenue for the first three quarters: 4.16 billion yuan, up 4.92% year-on-year [1] - Net profit attributable to shareholders: 748 million yuan, up 18.51% year-on-year [1] - Net profit after deducting non-recurring items: 746 million yuan, up 20.67% year-on-year [1] - Basic earnings per share: 0.84 yuan [1]

Financial Performance - The company's operating revenue for the third quarter reached CNY 1,289,540,392.43, representing a year-on-year increase of 7.37%[3] - Total profit for the quarter was CNY 259,492,598.49, reflecting a significant increase of 35.27% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 221,821,465.85, up 42.30% year-on-year[3] - The net profit after deducting non-recurring gains and losses was CNY 220,087,823.44, which is a 46.42% increase compared to the previous year[3] - The basic earnings per share for the quarter was CNY 0.25, an increase of 47.06% year-on-year[3] - The diluted earnings per share also stood at CNY 0.25, reflecting the same growth rate of 47.06%[3] - Total operating revenue for the first three quarters of 2025 reached ¥4,160,487,725.65, an increase of 4.9% compared to ¥3,965,261,223.17 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was ¥748,674,344.04, representing a 18.3% increase from ¥632,852,491.81 in 2024[20] - Total comprehensive income for the period reached CNY 752,435,984.63, an increase from CNY 628,981,441.03 in the previous period, representing a growth of approximately 19.6%[21] - Basic and diluted earnings per share increased to CNY 0.84, up from CNY 0.70, reflecting a growth of 20%[21] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was CNY 1,342,005,039.49, showing a substantial increase of 105.19%[3] - The company's cash and cash equivalents as of September 30, 2025, amount to ¥2,711,755,187.41, a decrease from ¥2,748,870,915.99 at the end of 2024[15] - The company has a total of 5,518,729,793.69 in current assets as of September 30, 2025, down from 6,071,494,807.15[15] - Net cash flow from operating activities for the first three quarters of 2025 was CNY 1,342,005,039.49, compared to CNY 654,028,177.61 in the same period of 2024, indicating a significant increase of approximately 104%[23] - Cash inflows from operating activities totaled CNY 4,725,571,418.11, up from CNY 3,947,477,914.32, marking an increase of about 19.6%[23] - Cash outflows from operating activities were CNY 3,383,566,378.62, compared to CNY 3,293,449,736.71 in the previous year, showing an increase of approximately 2.7%[23] - The ending cash and cash equivalents balance was CNY 2,567,368,061.39, slightly down from CNY 2,498,290,974.92 in the previous year[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 59,157[10] - Zhejiang Zhongbei Jiuzhou Group Co., Ltd. holds 31.88% of shares, totaling 283,518,812 shares[10] - The top ten shareholders include four individuals who are considered acting in concert, indicating potential influence on company decisions[11] - The company has not engaged in any share lending or borrowing activities during the reporting period[11] Liabilities and Equity - Total liabilities decreased to ¥1,894,528,281.50 from ¥2,517,671,243.17, reflecting a reduction of approximately 25%[17] - The company's equity attributable to shareholders increased to ¥8,755,178,673.48 from ¥8,536,673,816.75, showing a growth of 2.6%[18] Investments and Acquisitions - The company completed the acquisition of 100% equity in Hangzhou Zhuliang Pharmaceutical Technology Co., Ltd. for ¥22,193,000 on September 18, 2021[12] - The company plans to dissolve the joint venture Zhejiang Shangyao Jiuzhou Biopharmaceutical Co., Ltd. by September 2025, which will not impact the consolidated financial statements[13][14] Research and Development - Research and development expenses for the first three quarters were ¥194,755,936.65, down from ¥240,137,612.13, indicating a decrease of 18.8%[19] Non-Current Assets - The total non-current assets increased to ¥5,200,007,694.16 from ¥5,055,759,255.69, marking a growth of 2.9%[18] Accounting Practices - The company will not apply new accounting standards starting from 2025, maintaining its current accounting practices[26]

浙江九洲药业股份有限公司 子公司管理制度 浙江九洲药业股份有限公司 子公司管理制度 （2025 年 10 月修订） 第一章 总则 第一条 为了加强浙江九洲药业股份有限公司（以下简称"公司"或"九洲 药业"）子公司的管理，规范公司内部运作机制，维护公司和投资者合法权益， 根据《中华人民共和国公司法》（以下称"公司法"）、《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等法律、法规和规范性文件及《浙江九洲药 业股份有限公司章程》（以下称"公司章程"）的有关规定，结合公司经营发展实 际需要，制定本制度。 第二条 本制度适用于九洲药业子公司，即九洲药业根据战略规划和突出主 业、提高公司核心竞争力需要而依法设立、投资的，具有独立法人资格的境内子 公司，包括： （一）公司独资设立的全资子公司（含直接和间接持有）； （二）公司与其他法人和/或自然人共同出资设立的，公司持股比例在 50% 以上的控股子公司； （三）持股比例虽未达到 50%但能够决定其董事会半数以上成员的组成，或 者通过协议或其他安排能够实际控制的子公司。 境外子公司可参照适用本制度，如境外子公司所在国家或地区另有法律、法 规、规范性文件规定的， ...

浙江九洲药业股份有限公司 关联交易管理制度 浙江九洲药业股份有限公司 对外担保管理制度 （2025 年 10 月修订） 第一章 总则 第一条 为了维护投资者的利益，规范浙江九洲药业股份有限公司（以下简 称"公司"）的担保行为，控制公司资产运营风险，促进公司健康稳定地发展， 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》、 《上海证券交易所股票上市规则》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》以及《浙江九洲药业股份有限公司章程》（以下简称"公司章 程"）等的相关规定，制定本制度。 第二条 本制度所称担保是指公司以第三人身份为他人提供的保证、抵押或 质押，公司为子公司提供的担保视为对外担保。 第三条 本制度所称子公司是指全资子公司、控股子公司和公司拥有实际控 制权的参股公司。 第四条 子公司为公司合并报表范围内的法人或者其他组织提供担保的，公 司应当在子公司履行审议程序后及时披露，按照《上海证券交易所股票上市规则》 应当提交公司股东会审议的担保事项除外。 第六条 公司对外担保时应当采取必要措施核查被担保人的资信状况，并在 审慎判断被担保方偿还债务能力的基础上，决定 ...